Corcept Therapeutics Incorporated (LON: 0I3Q)

Market Cap	5.02B
Revenue (ttm)	468.96M
Net Income (ttm)	104.82M
Shares Out	n/a
EPS (ttm)	0.94
PE Ratio	47.91
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,379
Average Volume	628
Open	61.21
Previous Close	56.25
Day's Range	58.04 - 61.45
52-Week Range	20.76 - 61.45
Beta	n/a
RSI	64.86
Earnings Date	Feb 14, 2025

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 352
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0I3Q

Financial Performance

In 2023, Corcept Therapeutics's revenue was $482.38 million, an increase of 20.04% compared to the previous year's $401.86 million. Earnings were $105.50 million, an increase of 4.15%.

Financial numbers in USD